Inteum Company
Links
seedsprint
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Search Results - hyunsuk+shim
7
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
CXCR4-Targeting Molecules for Tumor Metastasis and PET Imaging
Application Positron emission tomography (PET) imaging agents with high specificity for metastatic cancer. Key Benefits 18F-labeled CXCR4 (partial) antagonist without stem cell mobilizing property is safe to be given to patient multiple times. Identifies tumor location non-invasively and provides an indication of tumor’s metastatic potential. Market...
Published: 7/30/2024
|
Inventor(s):
Hyunsuk Shim
,
Mark Goodman
,
Dinesh Shetty
,
Yoon Hyeun Oum
Keywords(s):
Imaging
,
Imaging Agents
Category(s):
TechPub Algolia > Diagnostics
Novel Piperidine-Amide Derivatives as CXCR4 Modulators
Application A new class of CXCR4 modulators for metastasis and inflammation. Key Benefits Selective for only one allosteric site on CXCR4. Lower adverse effects. Market Summary Activation of the CXCR4 receptor triggers multiple signaling pathways that orchestrate cell migration, hematopoiesis and cell homing, and retention in the bone...
Published: 7/30/2024
|
Inventor(s):
Hyunsuk Shim
,
Yoon Hyeun Oum
Keywords(s):
Immunology/Inflammation
,
Oncology
,
Small Molecule
Category(s):
TechPub Algolia > Therapeutics
HDAC Inhibitors for Managing Vascular Conditions and Diabetic Peripheral Neuropathies
Application Treatment of diabetic neuropathy using epigenetic modulators, histone deacetylase inhibitors (HDACis), to ameliorate or prevent vascular conditions and neuropathic pains by nerve damages. Key Benefits Reverses or protects against diabetes-induced nerve damages by direct injection of HDACi. Relatively low regulatory risk because many...
Published: 10/28/2024
|
Inventor(s):
Young-Sup Yoon
,
Ji Woong (Jay) Han
,
Hyunsuk Shim
Keywords(s):
Cell/Gene Therapy
,
Endocrinology
,
Metabolic Diseases
,
Repurposed Drug
,
Small Molecule
Category(s):
TechPub Algolia > Therapeutics
Chimeric Molecule for the Treatment of Depression
Application Small molecules for treating depression and/or depression associated with cancer/chemotherapy. Key Benefits Potentially a dual mechanism compound – working via monoamine reuptake inhibition and HDAC inhibition (epigenetic modification). Quicker acting compound compared to current therapies in the market. Works better than the...
Published: 8/22/2024
|
Inventor(s):
Hyunsuk Shim
,
Huw Davies
,
Hyun Min Park
,
Yoon Hyeun Oum
Keywords(s):
Neuroscience/Pain
,
Small Molecule
Category(s):
TechPub Algolia > Therapeutics
Web based Software for Whole-Brain Spectroscopic MRI in Patients with Neuropathologies (BrICS)
Application Web-based application for visualizing and analyzing spectroscopic MRI data (sMRI, MRSI) in diagnosing, treatment planning, and monitoring of neuropathologies such as tumor. Key Benefits Enables the analysis of multiple diagnostic images simultaneously. Generates a heat map of metabolite (e.g., CHO/NAA) levels to better diagnose malignancies. Incorporates...
Published: 10/28/2024
|
Inventor(s):
Hyunsuk Shim
,
Saumya Gurbani
,
Lee Cooper
,
Andrew Maudsley
,
Sulaiman Sheriff
Keywords(s):
Imaging
,
Neuroscience/Pain
,
Oncology
Category(s):
TechPub Algolia > Software
Derivatives as CXCR4 Modulators for the Treatment of Inflammation and Metastasis
Application Amide derivatives as chemokine receptor type 4 (CXCR4) modulators for the treatment of inflammation or prevention of cancer cell metastasis. Key Benefits Excellent binding affinity, compared to currently available compounds targeting CXCR4 receptor. Stability in plasma compared to protein/peptide agonists of CXCR4, these amide derivatives...
Published: 10/17/2024
|
Inventor(s):
Hyunsuk Shim
,
Renren Bai
,
Qi Shi
Keywords(s):
Immunology/Inflammation
,
Oncology
,
Small Molecule
Category(s):
TechPub Algolia > Therapeutics
CXCR4 Modulator for Preventing Cancer Metastasis
Application Amine derivatives as chemokine receptor type 4 (CXCR4) modulators to treat breast cancer and block tumor metastasis. Key Benefits New class of anti-cancer drugs targeting CXCR4 instead of COX pathway. Partial antagonists are safer for use because they do not mobilize stem cells. Market Summary CXC chemokine receptor 4 (CXCR4) and...
Published: 7/30/2024
|
Inventor(s):
Hyunsuk Shim
,
Renren Bai
,
Suazette Mooring
Keywords(s):
Immunology/Inflammation
,
Microbiology/Infectious Diseases
,
Oncology
,
Small Molecule
Category(s):
TechPub Algolia > Therapeutics